《新股消息》傳新石文化(01740.HK)公開發售超購逾1,000倍
市場消息指,今日(8日)截止招股的新石文化(01740.HK)公開發售超購逾1,000倍。
新石文化從事授出電視劇播放權許可、以非執行製作人身份投資電視劇,及擔任電視劇發行代理。是次在港上市計劃發售股份數目2.5億股,其中10%於本港公開發售,招股價介乎0.5元至0.74元,每手5,000股,入場費3,737.28元。股份預期於明日(9日)定價,1月16日掛牌上市。
以招股價中位數每股0.62元計,料是次上市集資淨額1.15億元,其中86.9%將用於製作電視劇,另外13.1%將用於購買與電視劇有關的版權或播放權。是次上市之獨家保薦人及獨家全球協調人為中泰國際。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.